There is a global trend to restrain AIDS pandemic, but currently 36.9 (34.3 -41.4) million people worldwide live with HIV/AIDS. According to 2011 UNAIDS data for the countries of Central and Western Europe, the total number of HIV+ persons was 1 million in Central Europe, 1 400 000 in Eastern Europe, and in Bulgaria -2380. Europe still fails to control HIV infection, and the situation is particularly alarming in the eastern regions. Combined antiretroviral therapy (cART) reduced morbidity and mortality rate in HIV/AIDS. [1] [2] [3] [4] With increasing access to cART, enhanced effi cacy, safety, tolerability and adherence to therapeutic regimens, HIV infection is defi ned as chronic manageable condition. [1] [2] [3] [4] [5] The introduction of cART resulted in increase of life expectancy of HIV+, but in some groups of patients lethality remains unacceptably high. [6] [7] [8] HIV infection prevalence is rather low in Bulgaria and yet the number of HIV-infected (HIV+) individuals in the country continues to grow. [1] [2] [3] Contemporary therapeutic regimens are accessible for HIV+ patients in Bulgaria 2 , but there are some factors as late diagnosis 'late presenters, with ad-Folia Medica I 2017 I Vol. 59 I No. 4 vanced immunodefi ciency' late treatment, respectively, and poor adherence to treatment that worsen the prognosis of the disease.
AIM
The aim of the study was to investigate the lethality and mortality rates in patients with HIV/AIDS, the most common causes and predictors of fatal outcome with the purpose of early diagnosis, monitoring and adequate intensive therapy.
MATERIALS AND METHODS
The study included 316 HIV/AIDS patients treated at the Clinic of Infectious Diseases in St George University Hospital, Plovdiv; 53 of them died in the period from 01.01.2010 to 31.12.2014. The methods used include clinical analysis, laboratory, microbiological, and parasitological tests, ELISA, PCR, and instrumental methods such as X-ray, ultrasonography, and endoscopy. Statistical analysis was carried out using descriptive statistics, the Student's t-test, and the method of Van der Waard regression analysis (logistic regression). Data from the records of the Regional Health Inspection on mortality in patients with tuberculosis and hepatitis C in the general population were used. Figure 1 shows the dynamics of HIV positive patients monitored from 2010 to 2014 at the Clinic of Infectious Diseases in St George University Hospital, Plovdiv.
RESULTS
The gender distribution of patients shows that men were prevalent (81% of the monitored and 80% of the deceased patients).
Analysis of age distribution (Fig. 2) showed that the largest proportion of patients was in the age group 25-35 yrs, and it was signifi cantly higher in monitored than in deceased patients (р<0.05, t=2.86). Signifi cantly higher was the share of the deceased against monitored patients in those aged up to 25 (12%, respectively 28% (р < 0.05, t=2.4). The number of patients over 60 years and below 18 years of age was too small in both groups.
The distribution of patients according to the mechanism of HIV transmission ( Fig. 3) was identical with that of the dead and survivors, the injection drug users being the most commonly affected.
Lethality in our patients in the study period showed minor fl uctuations in individual years, but did not show a decreasing trend (Fig. 4) .
Diseases associated with a fatal outcome were:
hepatitis C (HCV), pneumonia, candidiasis, cachexia and tuberculosis. In other patients the cause of death was meningitis, HSV infection, salmonella spp. infection -sepsis and pyonephrosis. Immunological and virological indicators CD4 (cells/mm 3 ) and VL (copies/μL) prior to the fatal outcome in the observed 53 patients were as follows: serum levels (mean, SD) of CD4 -54.23±48; VL -428 225±62 061. In 22/53 (41.5%) patients with fatal outcome CD4 count was < 50 cells/mm 3 . There were extremely low values of CD4 (6-25) cells/mm 3 in 12 patients.
The number of the deceased until the third month since start of therapy was the highest. By the end of the fi rst year it had dropped three times, but remained high compared to later periods (Fig. 5) .
A signifi cant difference was found between the lethality of tuberculosis in HIV+ and the general population (Р<0.01, t=3.4); the lethality of HBV in HIV+ and the general population (Р<0.05, t=2.4), and lethality from HCV in HIV+ and the general population (Р<0.001, t=4.3) ( Table 1) .
Using the Student's t-test we found signifi cant difference between the age in deceased from tuberculosis in AIDS patients -an average of 34 years, and the general population -an average of 56 years (Р<0.05, t=2.0) ( Table 2) .
Using multi-regression analysis we have studied the effect of CD4, VL, presence of TB, HBV and HCV infections. We found the infl uence of two independent risk factors on the lethal outcome of patients suffering from HIV infection. These were: CD4<100 (odds ratio 8.728; 95% confi dence interval 3.994-19.072; P=0.000) and VL>500 000 (odds ratio 4.169; 95% confi dence interval 1.207-14.405; P=0.024).
DISCUSSION
The prevalence of males among all our patients (monitored and dead), repeats the gender distribution in the country. Our data on gender distribution and mechanism of HIV transmission between monitored patients and those with lethal outcome is not fully consistent with data in the literature in other geographical regions. The reasons for the prevalence of the male sex are probably linked to the leading mechanisms of HIV transmission in the region -injection drug users (IDU) and men having sex with men (MSM), where males have a leading position. According to some authors mortality is higher among women and injection drug users (IVDU). 1 Other studies do not fi nd differences by gender 5, 7 but are almost unanimous in the opinion that lethality is highest in IVDU. [8] [9] [10] [11] The reasons for the high incidence of lethal outcome in IDUs are complex: higher frequency of coinfections HBV and HCV, cognitive impairment associated with drugs and poor adherence to therapy, marginalization of these persons and poor living conditions. The data on differences in age characteristics of the deceased and monitored patients are interesting. In our study, lethality was signifi cantly higher in the age group up to 25 years. A possible explanation is that most of them are IDU, and do not adhere to cART yet. Survey identifi ed data that lethality is of insignifi cant fl uctuations in the individual years without a trend to decrease, do not correlate with the data of other authors for sustained downward trend in the era of cART. 1, 2, 9 What might be the reasons for this inconsistency? Failure to adhere to therapy is crucial. Although the patient could have obtained suitable free cART, lack of adapting to a therapeutic regimen is disastrous.
It is important to defi ne the causes of deathwhether they are directly associated with HIV infection or not, since this implies different programs to decrease lethality. According to ARV Cohort Collaboration Study Group, 2010, AIDS related death is assumed in AIDS related infections and neoplasms, CD4 <50 cells/mm 3 , VL>5 log copies/μL before death, M Hodgkin, while unrelated to AIDS morbidity is assumed in co-infections and neoplasm, non-related to AIDS: HCV, HBV, HSV, M. tuberculosis infection, cardiovascular diseases, hematological conditions. 4 Differentiation of these two groups is very conditional, since the majority of patients with CD4 <50 cells/mm 3 also have tuberculosis, pneumonia or other infections unrelated to AIDS. The global reduction of mortality rate was achieved mainly by reducing AIDS-related mortality, resulting in a larger relative share of the other reasons for the fatal outcome related to comorbidity, co-infection with HCV, HBV, drug addiction and cardiovascular diseases.
Particularly noteworthy are data on the period in which death occurred since diagnosis, with extremely high mortality in the fi rst three months (76%), three times less patients die in the second quarter while the number drops sharply after the fi rst year.
Our data on early death (till the 6 th month since cART) in the vast majority of patients correlates with data of other authors. 5,6,10-13 A disturbing fact is that 22/53 patients with fatal outcome indeed have just started cART. Unfortunately, the diagnosis is too late, patients have advanced immune defi ciency, severe comorbidity (tuberculosis, pneumonia, meningitis) and die shortly after including cART. In cases of TB/HIV cART had to start some weeks There is disturbingly high prevalence and lethality in patients co-infected with HIV and TB. Tuberculosis was the leading cause of mortality in our patients. The strong synergy between HIV and TB has deadly consequences worldwide, especially among populations with high prevalence of HIV (sub-Saharan Africa, India). HIV pandemic is a huge challenge on TB control at all levels [14] [15] [16] -patients are ill with AIDS, but die from tuberculosis! In patients with HCV co-infection lethality was 26/146 (17.8%), two patients died with signs of hepatic coma. Data of many authors indicate that lethality in patients on cART tends to decrease, but not if they have HIV/HCV co-infection. HCV is defi ned as a risk factor for adverse outcomes in patients with AIDS. 5, 6, 14, 15 Limitations of the study: there are no pathological autopsies, not all patients have died at the Clinic, part of the data on CD4 and VL are not actual, but the latest available, due to the irregular appearance of the patients for monitoring.
CONCLUSION
Fatal outcome occurs most commonly in patients aged up to 35 years, with advanced immunodefi ciency and tuberculosis, pneumonia or hepatitis HCV. The most risky period includes the fi rst six and particularly the fi rst three months from start of cART. The causes of death in monitored patients are AIDS-related and the greatest effect on reducing the lethality is early diagnosis and timely cART.
